CDK5 and urinary bladder cancer: Higher expression of CDK5 was observed in hepatocellular carcinoma, ampullary adenocarcinoma, breast cancer, and medullary thyroid carcinoma, and Zachary et al. confirmed the expression of CDK5 was upregulated in colorectal, head/neck, breast, lung, ovarian, lymphoma, prostatic, sarcoma, myeloma, and bladder cancers via the Oncomine microarray online data mining software [11, 12, 18, 28].